It must be shared, world-wide -- at cost, though. That's a moral imperative. The central question will be logistics, and whether multiple other manufacturers will be offered a non-exclusive, co-licensed right/agree to run full-on production, flat out, on essentially all the sophisticated vaccine facilities' lines. . . now in existence. I think a new US Administration, appealing to the industry's higher purpose, will get it done. And I think the nobler instincts of the EU, China and Japan -- and the UK will come to the fore.
That is my hope. This is the likely safest way we find our way out, of these death-darkened times. Here is is the report from Reuters, among many others reporting this morning:
. . . .The data are from eight people who took part in a safety trial that kicked off in March as the global pandemic caused by the novel coronavirus was spreading.
In the trial of 45 volunteers, conducted by the National Institute of Allergy and Infectious Diseases, eight volunteers who got two doses of the vaccine produced protective antibodies roughly on par with people who recovered from a natural infection of the virus that causes the COVID-19 illness, the U.S. biotechnology company said in a news release.
The study, which was not designed to prove the vaccine works, offered an early glimmer of hope that it could provide protection against the virus. . . .
Again -- just green shoots, but the task before us no longer looks. . . out of reach. Together, we will solve this. And, in the mean time, be excellent to one another -- wear your mask -- as the river runs through it. . . .
नमस्ते
No comments:
Post a Comment